U.S. markets open in 2 hours 44 minutes

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4000+0.0400 (+11.11%)
At close: 12:35PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3600
Open0.3700
Bid0.3300 x 0
Ask0.4000 x 0
Day's Range0.3500 - 0.4000
52 Week Range0.1000 - 0.5800
Volume24,000
Avg. Volume45,416
Market Cap13.701M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
      ACCESSWIRE

      RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference

      Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company Pitch SessionVANCOUVER, BC / ACCESSWIRE /February 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced its President and CEO, R.

    • RepliCel Closes First Tranche of Strategic Investment Commitment
      ACCESSWIRE

      RepliCel Closes First Tranche of Strategic Investment Commitment

      MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment AgreementVANCOUVER, BC / ACCESSWIRE / February 10, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the first tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed earlier this year by the parties.

    • ACCESSWIRE

      RepliCel CEO Provides Corporate Update

      Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF)(FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its Board and Management represented by President and CEO, Mr.